Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

Efimenko et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.096
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 69% Improvement Relative Risk Ivermectin  Efimenko et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? PSM retrospective 41,608 patients in the USA (Jan 2020 - Jul 2021) Study compares with remdesivir, results vs. placebo may differ Lower mortality with ivermectin (p<0.000001) Self-censored, see notes c19ivm.org Efimenko et al., Int. J. Infectious Di.., Feb 2022 Favorsivermectin Favorsremdesivir 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 109 treatments. c19ivm.org
PSM retrospective 41,608 patients in the USA, 1,072 treated with ivermectin and 40,536 treated with remdesivir, showing lower mortality with ivermectin treatment.
This study was presented at a conference (IMED 2021). Submissions were peer-reviewed. The treatment/control group sizes align with the estimated percentage of hospitals that used ivermectin vs. remdesivir. Hospitals in the USA receive financial incentives to use remdesivir.
Authors have self-censored the conference report of this result, not due to any error in the analysis, but because they believe ivermectin "has proven to be ineffective in clinical trials". This is incorrect, while some studies show no statistically significant effect, 64 studies show statistically significant positive results for one or more outcomes (37 prospective and 27 retrospective studies, including 27 RCTs)1-64.
The self-censorship and decision not to submit to a journal provide further evidence of a negative publication bias for ivermectin research.
This is the 80th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).
52 studies are RCTs, which show efficacy with p=0.00000021.
risk of death, 69.2% lower, OR 0.31, p < 0.001, treatment 1,072, control 40,536, propensity score matching, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Efimenko et al., 28 Feb 2022, retrospective, propensity score matching, USA, peer-reviewed, 6 authors, study period 1 January, 2020 - 11 July, 2021, dosage not specified, this trial compares with another treatment - results may be better when compared to placebo.
This PaperIvermectinAll
Development of Duplex and Multiplex Reverse Transcription Loop Mediated Isothermal Amplification (RT-LAMP) Assays for Clinical Diagnosis of SARS-COV-2 in Sri Lanka
M Hewadikaram, K Perera, K Dissanayake, M Ramanayake, S C Isurika, A Panch, A Jayarathne, P Pushpakumara, N Malavige, C Jeewandara, S D N K Bathige, A M Mubarak
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.095
Purpose: Despite the rollout of several vaccines targeting SARS-CoV-2, attainment of near-universal vaccination is a challenging task, particularly for low-and middle-income nations such as Sri Lanka. Rapid, reliable diagnostics for the detection of the virus is of vital importance for the predominantly export-and tourismbased economy of the country. Herein, we report the development of a RT-LAMP assay as an alternative to the gold-standard RT-qPCR method for diagnostic laboratories in Sri Lanka in a cost-effective and highly reliable manner. Methods & Materials: About 313 nasopharyngeal and oropharyngeal samples from the community were collected and subjected to RNA purification and subjected to simultaneous RT-qPCR and RT-LAMP experiments by using previously published primers in a thermocycler. Duplex (containing N and E gene primers) and multiplex (containing N, E and ORF1ab gene primers) RT-LAMP assay results were compared with standard RT-qPCR results using an agreement attribute statistical test. The effect of guanidine hydrochloride was also analyzed. Results: The limit of detection for the duplex assay was found to be 10 copies μL-1 at a constant temperature of 63 °C, and 5 copies μL-1 for multiplex assays at 66.4 °C. Both types of RT-LAMP assay were specific only for the SARS-COV-2 virus, successfully distinguishing it from multiple other human viruses. Attribute agreement analysis between duplex-and multiplex RT-LAMP vs RT-qPCR yielded 93% and 96.5% scores, respectively. Moreover, both RT-LAMP assays showed 100% agreement with RT-qPCR when Ct was < 25 in positive samples and showed 100% (duplex) or 97.22% (multiplex) at 35 ≥ Ct ≥25. The discrepancy between agreements at higher Ct values was attributed to the higher sensitivity of the multiplex RT-LAMP assay. The addition of guanidine hydrochloride increased the sensitivity and decreased detection time significantly for both the duplex and multiplex assays. Conclusion: Overall, we have demonstrated a potentially rapidly deployable diagnostic test kit not only for widespread community use but particularly for high-risk locations such as ports of entry or manufacturing facilities to mitigate the effects of the SARS-CoV-2 virus in Sri Lanka.
{ 'indexed': {'date-parts': [[2022, 3, 1]], 'date-time': '2022-03-01T00:14:48Z', 'timestamp': 1646093688074}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 3, 1]], 'date-time': '2022-03-01T00:00:00Z', 'timestamp': 1646092800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 12, 12]], 'date-time': '2021-12-12T00:00:00Z', 'timestamp': 1639267200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': ['International Journal of Infectious Diseases'], 'published-print': {'date-parts': [[2022, 3]]}, 'DOI': '10.1016/j.ijid.2021.12.096', 'type': 'journal-article', 'created': {'date-parts': [[2022, 2, 28]], 'date-time': '2022-02-28T23:44:22Z', 'timestamp': 1646091862000}, 'page': 'S40', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: ' 'Analysis of a National Federated Database'], 'prefix': '10.1016', 'volume': '116', 'author': [ {'given': 'I.', 'family': 'Efimenko', 'sequence': 'first', 'affiliation': []}, {'given': 'S.', 'family': 'Nackeeran', 'sequence': 'additional', 'affiliation': []}, {'given': 'S.', 'family': 'Jabori', 'sequence': 'additional', 'affiliation': []}, {'given': 'J.A. Gonzalez', 'family': 'Zamora', 'sequence': 'additional', 'affiliation': []}, {'given': 'S.', 'family': 'Danker', 'sequence': 'additional', 'affiliation': []}, {'given': 'D.', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': ['International Journal of Infectious Diseases'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971221009887?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1201971221009887?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 2, 28]], 'date-time': '2022-02-28T23:44:22Z', 'timestamp': 1646091862000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3]]}, 'references-count': 0, 'alternative-id': ['S1201971221009887'], 'URL': 'http://dx.doi.org/10.1016/j.ijid.2021.12.096', 'relation': {}, 'ISSN': ['1201-9712'], 'issn-type': [{'value': '1201-9712', 'type': 'print'}], 'subject': ['Infectious Diseases', 'Microbiology (medical)', 'General Medicine'], 'published': {'date-parts': [[2022, 3]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit